Cellectar Biosciences Confirms Nasdaq Listing for CLRB Stock

TL;DR

**CLRB confirms Nasdaq listing, business as usual.**

AI Summary

Cellectar Biosciences, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024. This filing indicates that the company's Common Stock, with a par value of $0.00001 per share, is registered on The Nasdaq Capital Market under the trading symbol CLRB. This matters to investors because it confirms the company's continued listing and compliance with exchange requirements, providing liquidity and transparency for shareholders.

Why It Matters

This filing confirms Cellectar Biosciences' continued listing on The Nasdaq Capital Market, which is crucial for maintaining investor confidence and ensuring the stock's liquidity and visibility.

Risk Assessment

Risk Level: low — This filing is purely administrative, confirming existing information, and does not introduce new financial or operational risks.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the company's continued presence on a major exchange, but it doesn't provide new information to drive investment decisions.

Key Numbers

• $0.00001 — par value per share (the stated par value of Cellectar Biosciences' Common Stock)

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Capital Market (company) — the exchange where Cellectar Biosciences' stock is registered
• CLRB (company) — the trading symbol for Cellectar Biosciences' Common Stock
• $0.00001 (dollar_amount) — the par value per share of Common Stock
• January 8, 2024 (date) — the date of the earliest event reported
• January 9, 2024 (date) — the filing date of the 8-K

Forward-Looking Statements

• Cellectar Biosciences will maintain its listing on The Nasdaq Capital Market. (Cellectar Biosciences, Inc.) — high confidence, target: 2025-01-08

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M

Filing Documents

• tm242431d1_8k.htm (8-K) — 25KB
• tm242431d1_ex99-1.htm (EX-99.1) — 18KB
• tm242431d1_ex99-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-24-002401.txt ( ) — 222KB
• clrb-20240108.xsd (EX-101.SCH) — 3KB
• clrb-20240108_lab.xml (EX-101.LAB) — 33KB
• clrb-20240108_pre.xml (EX-101.PRE) — 22KB
• tm242431d1_8k_htm.xml (XML) — 3KB

01

Item 8.01. Other Events. On January 8, 2024, the Company issued a press release providing topline data from its Waldenstrom's macroglobulinemia CLOVER-WaM pivotal trial. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release, dated January 8, 2024, entitled, "Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: January 8, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR